Hantavirus explained: What to know after the cruise ship outbreak
Stay strong at any age with 4 basic exercises
Why testosterone levels drop and when to consider treatment
Don't count on daily aspirin to prevent colon cancer
Night owls' habits linked to worse heart health
After ablation, exercise may lower atrial fibrillation recurrence
What can cause an enlarged heart?
Women's unique risks for heart disease
Chronic kidney disease: A hidden threat to your heart
Navigating your online patient portal: Best practices
Guru P. Sonpavde, MD
Contributor
Guru P. Sonpavde, MD is the director of the bladder cancer program at Dana-Farber Cancer Institute and is on the faculty of Harvard Medical School. He completed his medical oncology fellowship at Indiana University. His primary focus is on clinical trials to develop new drugs and combinations to treat urologic cancers, particularly bladder cancer. He also has led translational projects and developed prognostic classifications and endpoints focused on bladder cancer. He is a member of the Genitourinary Committee of Southwest Oncology Group and the Bladder Cancer Task Force of the National Cancer Institute Genitourinary Steering Committee.
Posts by Guru P. Sonpavde, MD
Guru P. Sonpavde, MD
Cancer treatment: Is a clinical trial right for you?
Healthy aging and longevity
Immunotherapy: What you need to know
Hantavirus explained: What to know after the cruise ship outbreak
Stay strong at any age with 4 basic exercises
Why testosterone levels drop and when to consider treatment
Don't count on daily aspirin to prevent colon cancer
Night owls' habits linked to worse heart health
After ablation, exercise may lower atrial fibrillation recurrence
What can cause an enlarged heart?
Women's unique risks for heart disease
Chronic kidney disease: A hidden threat to your heart
Navigating your online patient portal: Best practices
